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 INTRODUCTION 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
            High performance liquid chromatography is a very sensitive analytical technique 
most widely used for quantitative and qualitative analysis of pharmaceutical. The 
principle advantage of HPLC compared to classical column chromatography is 
improved resolution of the separated substance, faster separation times and the 
increased accuracy, precision and sensitivity. 
PRINICIPLE OF HPLC  
           The principle of separation in normal phase mode and reverse phase mode is 
adsorption. The component which has more affinity towards the adsorbent travels 
slower. The component which has less affinity towards the stationary phase travels 
faster. Since 2 components have the same affinity towards the stationary phase, the 
components are separated.  
INSTRUMENTATION OF HPLC 
 
1) Solvent reservoirs                                    
2)  Solvent degasser 
3)  Gradient valve  
4)  Mixing vessel for delivery of the mobile phase 
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5)  High-pressure pump  
6)  Switching valve in "inject position" switching valve in "load position"  
7) Sample injection loop 
8) Pre-column   
9) Analytical column                                                                                                                           
      10) Detector (i.e. IR, UV)  
     11)  Data acquisition 
     12)  Waste or fraction collector 
Solvent delivery system  
• Ability to mix solvents and vary polarity of mobile phase during run 
• Unlimited solvent reservoir 
• Generation of pressure to 6000 psi 
• Flow rates ranging from 0.1 to 10 mL/min 
• Flow reproducibility of 0.5% or better  
• Resistance to corrosion by a variety of solvents 
• Plus free out put  
Degasser  
• Vacuum pumping systems 
• Distillation system  
• A system for heating and stirring the system  
• Spraying system bubbles an inert gas of low solubility through the solvent    
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Three basic types of pumps are used  
• Pneumatic pumps  
• Motor driven syringe type pumps 
• Reciprocation pumps 
Gradient controller 
• The gradient controller is the device that allows you to create a gradient program. 
• Gradient are produced differently for different types of pumping system.   
Injectors   
• Sample injection systems 
• Rubber stopper injector or syringe  
• Sample value   
Guard column  
            Remove impurities from solvent saturates mobile phase with liquid of stationary 
phase before the analytical column, straight: 15 to 150 cm in length; 2 to 3 mm and 
packing - silica gel, alumina, celite.  
 Packing  
            Originally these were irregular silica and alumina a range synthetic regular 
shape is available now, 
 Porous:                        Channels through packing. 
 Superficial porous:    Rough surface.  
 Smooth:                        Like bead.  
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Common reverse phase solvents 
 Methanol, acetonitrile, tetrahydrofuran, water  
Normal phase solvents  
 Amino (-NH2), Cyano (-CN), diol (glycidoxy-ethyl methoxide)  
Detector 
o Mostly optical 
o Equipped with a flow cell 
o Focus light beam at the center for maximum energy transmission 
o Cell ensures that the separated bands do not wide 
Types of detector 
 UV/Visible  
- Fixed wavelength 
- Variable wavelength 
 Photo idode array 
 Refractive index 
 Fluorescence 
 Evaporative light scattering 
 Conductivity 
 Electrochemical 
 Chiral detectors 
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Application of HPLC in the pharmaceutical industry 
          Manufacturing, content uniformity, degradation products and related substances, 
dissolution and stability studies.  
Definition of validation (As per USP) 
          Validation of an analytical procedure is the process by which it is 
established, by laboratory studies, that the performance characteristics of the 
procedure meet the requirements for the intended analytical applications. 
Methodology 
 The real goal of the validation process is to challenge the method and determine 
the limits or allowed deriability for the condition needed to the method. 
Types of analytical procedure to be validated 
 1. Identification test 
 2. Quantitative test for impurities contents 
 3. Limit test for the control of impurities 
 4. Quantitative test of the active molecule in samples of drug substance or drug 
product 
Specificity 
 An investigation of specificity should be conducted during the validation of 
identification test, determination of impurities and assay. 
Linearity 
 The linearity of an analytical procedure is of ability (within a given range) to 
obtain test result while are directly proportional to the concentration of analyte in the 
dam pole for establishment of linearity. A minimum of 5 concentrations is recommended 
other approaches would justify. 
Range 
• The range of analytical procedure is introduced between the higher and lower 
concentration of analyte in the sample. 
• For assay of drug substance: Normally from so to use of the test concentration. 
• For content uniformity :- 70-80% of the concentration 
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• For dissolution release product 20% another one hour up to 40% after 24 hour for 
the validating range would be 0-100% of the label claim.      
Accuracy 
 Accuracy on the method was determined by relative and absolute recovery 
experiments. 
Precision 
 Validation of test for assay and quantitative determination of impurities includes 
an included an investigation of precision. 
Detection limit  
               The detection limit of an individual analytical procedure is the lowest amount of 
analyte is a sample which can be detected but not necessary quantified as an exact 
value. 
Quantification limit 
The quantitative limit of an individual analytical procedure is the lowest amount of 
analyte in the sample which can be quantitative determined with suitable precision and 
accuracy.  
Robustness 
       The  robustness  of  the  method  was  assessed  by  altering  the  some  
experimental conditions such as, by changing the flow rate from 0.9 to1.1 mL/min,  
amount of diluents (10% to 15%) the temperature of the column  (28°C to 32°C) and pH 
of the mobile phase 
System stability testing  
             It is an integral of many analytical procedures. This based on the concept that 
the equipment electronics analytical operation and samples. 
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LITERATURE REVIEW 
Geetha Susmita A et al., 2015 established the simultaneous estimation of 
acebrophylline and acetylcysteine   in tablet dosage form by RP-HPLC method. An 
enable Hypersil BDS, C18, 100 x 4.6 mm5μ particle size column was used as stationary 
phase. The mobile phase consisting of a mixture of buffer solution and acetonitrile 
(90:10) was pumped isocratically at a flow rate of 1 mL/min with detection at 260nm. 
The retention time of acebrophylline and N-acetylcysteine were found to be 5.5 min and 
2.3 min respectively. The calibration curves were linear over a concentration range of 
25-150 µg/mL with coefficient regression (r2) = 0.9995 and (r2) = 0.9996 for 
acebrophylline and N-acetylcysteine. The  limits  of  detections  were  0.18  μg/mL  and  
1.50  μg/mL  for  acebrophylline & N-acetylcysteine respectively. The selectivity, 
specificity, system suitability, ruggedness and robustness were performed as per ICH 
guidelines. In  quantitative  and  recovery  studies  was  100.37%  and  100.8%  for  
acebrophylline  and  N-acetylcysteine   respectively.  
Shukla Khushboo N et al., 2015 propose of this development of new analytical 
methods and their validation for the determination of acetylcysteine in bulk and 
marketed formulation. Method IA, NAC gives light brown colour with ninhydrine in 
alkaline medium, which showed λmax at 485.2nm. The drug was reacted with fehling’s 
solutions (A&B in equal volume) and ferric chloride, which produce yellow colour 
chromogen which showed λmax at 537.2 nm. The linearity range of 50-300μg/mL for both 
method IA and method IB. The correlation coefficient is 0.9990 and 0.9991. The LOD 
and LOQ for estimation of NAC were found as 0.0773, 0.2343 for method IA and 
0.0667, 0.2021 for method IB respectively formulations.  
Tvinkal P et al., 2015 have reported developed and validated for the simultaneous 
estimation of acebrophylline and acetylcysteine in tablet dosage form by absorbance 
ratio method. Acebrophylline  and  acetylcysteine   were  found  to  have  absorbance  
maxima  at 274  and  195  nm respectively in distilled water and iso absorptive point 
was found to be 210nm.  Acebrophylline  was  found  to  be  linear  in  the  
concentration range of 5 to 11 μg/ mL at 274  nm and acetylcysteine was found to be 
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linear  in  the concentration  range  of  30  to 66 μg/mL at 195 nm. The assay of 
marketed tablet formulation (Pulmo clear tablet) was found to be 103.4% and 101.58% 
for acebrophylline and acetylcysteine respectively. The method was validated 
statistically as per ICH guidelines. The method showed good reproducibility and 
recovery with % RSD less than 2. 
Nitin S et al., 2014 reported validated RP-HPLC method development for the 
simultaneous estimation of acetylcysteine  and acebrofylline in capsule formulation a 
new simple, precise, rapid and accurate reverse phase high performance liquid 
chromatographic method had been developed or the simultaneous estimation of 
acetylcysteine (ACST) and acebrofylline (ACBF) in capsule dosage form. The 
chromatographic separation was achieved on a Hypersil BDS, C18, 100 x 4.6 mm, 5µm 
particle size column was used with PDA detemine by using mobile phase  containing 
mixture of 0.02M potassium dihydrogen orthophosphate (KH2PO4) buffer: acetonitrile 
(90:10 % v/v pH 3.2) was used. The flow rate was 0.9mL /min and effluents were 
monitored at 260 nm. Chromatogram showed two main peaks corresponding to 
acetylcysteine and acebrofylline at retention time 2.365 and 5.505 min respectively. The 
method was linear over the concentration range of 150-900µg/mL for acetylcysteine and 
25-150 µg/mL for acebrofylline respectively. 
Mangelings D et al., 2014 reported development and validation of an HPLC method 
with post column derivatisation for assay of n-acetylcysteine in plasma determination of 
both low endogenous and high therapeutic concentrations of N-acetylcysteine (NAC) in 
plasma. The compound is detected fluorimetrically after derivatisation with ortho-
phthalaldehyde in the presence of a primary amine. Validation of the method revealed 
injection and method repeatability was good. The linear range was adequate and the 
limit of quantification was between 0.4 and 0.6µM. Recovery of N-acetylcysteine from 
plasma samples was also acceptable. This method was applied to plasma samples 
from patients. Six samples were taken at different times after administration of N-
acetylcysteine. 
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Asiya Begum et al., 2014 to established a development and validation of 
acetylcysteine and taurine tablet dosage form by using RP-HPLC using the isocratic 
separation method Inertsil ODS (250 x 4.6 mm, 5 μm) column and potassium using 
dihydrogen OPA: acetonitrile (60:40) Mobile phase as pumped at a rate of 1mL/min the 
detection was carried out 248nm. The retention time is found in the range of 3.186 and 
4.142 minutes. The percentage assay of acetylcysteine and  taurine were  99% and 
100%.The linear regression analysis data for the calibration plots showed   a good  
linear  was found to be in the range of  acetylcysteine and taurine over  a  concentration 
range of  1000-3000  μg/mL  and  300-900μg/mL with correlation co-efficient of  0.999 
for acetylcysteine and  0.999 for taurine. The limit of detection and quantitation were 
found to be 2.93, 2.76 & 9.75, 9.20 respectively.  
Mogili Swetha et al., 2013 have reported RP-HPLC method for estimation of 
acetylcysteine   and taurine in API and pharmaceutical dosage form development and 
validation for the simultaneous estimation of acetylcysteine and taurine in tablets using 
a Agilent C184.6×150mm.5μ column, mobile phase comparied of 0.01N KH2PO4 and 
methanol in the ratio of 60:40v/v and flow rate is 1mL/min. The linearity was in the range 
of 300-900μg/mL; hence the RP-HPLC method developed and validated can be used 
routinely for the simultaneous estimation of acetylcysteine and taurine in tablets. 
Tessier Neirinick et al., 2013 reported novel sensivity ursodeoxycholic acid and its 
glycine and taurine conjugates in human plasma. solid phase extraction of UDCA, 
GDCA, TDCA and the internal standard, 23- nordeoxycholic acid from human plasma 
on a C18.Chromatography was performed by isocratic reverse phase separation with 
methanol/25 mM ammonium acetate (40/60, v/v) containing 0.05% acetic acid 
C18column with embedded polar functional group. Linearity of glycine and taurine of 10–
3000 μg/mL average correlation coefficient of 0.9992. The absolute recovery for UDCA, 
GDCA, TDCA and the internal standard was 87.3, 83.7, 79.5 and 95.8%, respectively. 
Marine De Person et al., 2012 have reported development and validation of a 
hydrophilic interaction chromatography-mass spectrometry assay for taurine and 
methionine in matrices rich in carbohydrates developed and validated for the 
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simultaneous determination of underivatised taurine and methionine rich in 
carbohydrates such as energy drinks column Astecap Hera NH2 (150 mm × 4.6 mm; 
5 μm) methanol–water (60/40) as mobile phase. Threonine as the internal standard for 
specifity, detection limits, linearity, accuracy, precision and stability limit of detection 
20 μg L−1 for taurine to 50 μg L−1 for methionine. 
Athawale Rajani et al., 2012 have reported phase development and validation of RP-
HPLC method for the estimation of N-acetylcysteine in wet cough syrup. C18 (150mm X 
4.6 mm i.d., particle size 3.5µm) column. The gradient flow system was used. Mobile 
phase consisting of acetonitrile and 0.05M phosphate buffer (pH was adjusted to 
3.0+0.05 by using orthrophosphoric acid), flow rate is 0.8 mL/min maintain the ambient 
temperature. Detection was carried out at 214nm. The retention time of about 4.6 
minutes was recorded. Linear over the concentration range of 400-600 µg/mL 
(R=0.999). The proposed method was applicable to routine analysis of acetylcysteine in 
wet cough syrup dosage form.  
 Paraskevas D et al., 2012 reported HPLC method for determination of N-
acetylcysteine   using post-column derivatization with methyl -propiolate a new, green 
analytical method is proposed for the determination of N-acetylcysteine (NAC) in 
pharmaceutical formulations. The analyte was separated from the samples matrix using 
a 100% aqueous mobile phase [0.05% v/v 
CH3COOH+1 mol L−1 ethylenediaminetetraacetic acid (EDTA) in water] and a suitable 
analytical column (Prevail reversed phase column). Detection was carried out at 285nm 
after on-line post column derivatization (PCD) with methyl- propiolate (MP) in alkaline 
medium. Method development included both chromatographic and reaction parameters, 
while validation was based on international recommendations. 
Aline Ferreira Ourique et al., 2011 have reported the method involves the use of 
phase column, and a mixture of 0.05 M the reversed KH2PO4 and acetonitrile (95 : 5v/v) 
containing 0.095% (v/v) of phosphoric acid, as the mobile phase. UV detection was 
performed at 214 nm linear response was observed over the concentration range 
between 10 and 50 μg mL−1 of NAC. Validated with the official guidelines for specificity, 
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linearity (r = 1), detection and quantification limits (0.70 and 2.11 μg mL−1), precision 
(RSD < 2%), accuracy (recovery > 97%), and robustness (RSD < 4%). Therefore, NAC 
can be assayed in granules and effervescent tablets using the same chromatographic 
conditions without derivatization.   
Emillia Marchei et al., 2011 have reported  development and validation of a high-
performance liquid chromatography–mass spectrometry assay for methylxanthines and 
taurine in dietary supplements a C18 reversed-phase column using 
water:methanol:acetic acid 75:20:5 as a Mobile phase analytes were determined in LC–
MS single ion monitoring mode with atmospheric pressure ionization-electrospray (ESI) 
interface. Sample specimens were extracted with 4 mL of hexane/isopropanol (9:1). 
Validated in the taurine and caffeine range is 0.1–500 and 0.06–500 μg/mL or μg/g and 
caffeine, respectively; 0.06–100 μg/mL or μg/g for theobromine and theophylline. Mean 
recoveries ranged between 70.1 and 94.4% for different analytes. The quantification 
limits were 0.1 μg/mL or μg/g for taurine and 0.06μg/mL or μg/g for methylxanthines 
either in liquid samples or solid samples. 100 to 1000μg/mL amount of taurine present 
in the energetic drinks. 
Zhi Chen et al., 2006 reported HPLC/ESI-MS method for the simultaneous 
determination of taurine and 10 water-soluble vitamins including vitamin B1 (thiamine), 
B2 (riboflavin), B5 (pantothenic acid), B6 (pyridoxine and pyridoxal), B8 (biotin), B9 (folic 
acid), C (ascorbic acid) and PP (nicotinamide and nicotinic acid) in multivitamin tablets 
was developed and validated. The separation was accomplished on a Johnson 
Spherigel C18 (250 mm×4.6 mm) reversed phase column with methanol in an aqueous 
solution of heptafluorobutyric acid (5 mm) as mobile phase  under gradient elution 
mode. Detection of target components was by ESI-MS switching continuously from 
positive ion mode to negative ion mode hippuric acid was used as an internal standard 
for quantification. Sensitivity, precision and accuracy were determined. 
Vander Heyden Y et al., 2004 reported that developed enables determination of both 
low endogenous and high therapeutetic concentrations of N-acetylcysteine (NAC) in 
plasma. The linear range was adequate and the limit of quantification was between 0.4 
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and 0.6 µM. Recovery of N-acetylcysteine from plasma samples was also acceptable. 
This method was applied to plasma samples from patients with a clinical septic shock 
who had received very high doses of N-acetylcysteine. Six samples were taken at 
different times after administration of N-acetylcysteine. The blood-concentration profiles 
obtained indicate the method is suitable for following the evolution of NAC in plasma 
under these conditions and can therefore be used for pharmacokinetic profiling. N-
Acetylcysteine (NAC) is mainly used as a mucolytic in bronchitis or pulmonary diseases. 
By depolymerising mucopolysaccharides it reduces the viscosity of pulmonary 
secretions.  
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AIM AND PLAN OF WORK 
           The drug analysis plays an important role in the development of drugs, their 
manufacture and the therapeutic use. Pharmaceutical industries rely upon quantitative 
chemical analysis to ensure that the raw materials used and final product obtained 
meets the required specification. The number of drugs and drug formulations introduced 
in to the markets has been increased at a disturbing rate. These drugs or formulation 
may be either in the new entities in the market or partial structure modification of the 
existing drugs or novels dosage forms or multi component dosage forms.  
AIM OF WORK 
            The present work aims at developing newer analytical methods for 
acetylcysteine and taurine in tablet dosage forms by using RP-HPLC, that are simple, 
accurate, rapid, precise, sensitive and reliable.  
PLAN OF WORK 
           To validated a method for analytical quantitation of assay in acetylcysteine and 
taurine in tablets dosage form. 
          To give a general ICH guidelines for the validation of methods aim for the 
quantitation of acetylcysteine and taurine in tablets dosage form. 
           Obtaing results with improved accuracy and precision. 
OBJECTIVE OF WORK 
            To develop analytical and validation method for the estimation of of 
acetylcysteine and taurine in tablet dosage form by using RP-HPLC method. 
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DRUG PROFILE OF ACETYLCYSTEINE 
Structure  
 
            
N HO
OH
C H 3
O S H  
Molecular weight  163.5 
Molecular formula C5H9NO3S  
Chemical name  (2R)-2-acetamido-3-sulfanylpropanic acid  
Description  It is a white with light yellow cast powder has a pKa of 9.5 at 
30 °C.   N- acetylcysteine is derived from the sulfur-containing 
amino acid            
Adverse effects  
                                
Rash, urticaria, itchiness, anaphylaxis reaction, hypotension, 
wheezing, shortness of breath, lower rates of anaphylactoid 
reaction, stomatitis and rhinorrhea 
Pharmacodynamic Acetylcysteine serves a prodrug to L- cysteine. Acetylcysteine 
also known as N-acetylcysteine or N-acetyl-L-cysteine (NAC) is a 
medication use treatment of paracetamol overdose 
(acetaminophen) 
Solubility  Soluble in water and alcohol. Insoluble in chloroform and ether 
Route of 
administration  
By oral, inhalation and injection. 
Uses Mucolytic theraphy, hemorrhagic cystitis, nephroprotective agent, 
obstructive lung disease and psychiatry 
ATC Code R05CB01(WHO)S01×A08(WHO)V03B23 
Bioavailability  10% (oral) 
Protein binding  50 to 83% 
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Metabolism  Liver 
Biological half life  5-6 hours 
CAS number 616-91-1 
 
 
Dosage form  
Solution for inhalation – inhaled mucolytic therapy or ingested 
for nephroprotective effect                                             
Intravenous injection – treatment of acetaminophen overdose  
Oral solution – various indications.                                           
Ocular solution - for mucolytic therapy. 
Sensitivity 
reaction 
Anaphylactoid reactions                                                                    
other allergic reactions                                                                     
Generalized urticaria reported rarely                                                 
Warning  Encephalopathy due to hepatic failure, respiratory effects, 
observes asthmatic patients closely. When administered intra 
veneous caution in patients with asthma or history of 
bronchospasm. 
Pharmacokinetics Extensively liver metabolized, CYP450 a minimal. Urine excretion  
22-30%, half-life of 5.6 hours in adults and 11 hours in neonates 
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DRUG PROFILE OF TAURINE 
Structure 
N H 2
SOH
O
O
    
Chemical name  2- amino ethane-1-sulphonic acid 
Molecular formula C2H7NO3S 
molecular weight 125.14 
density  1.734g/cm3 
Melting point  305.11οC                                
Therapeutic uses Treatment of cardiac and metabolic disease 
Brand name Bestoxol, Genferon and Taufon   
Biological role  Congication of bile acids, antioxidation, osmoregulation, 
membrane stabilitilization, modulation of calcium signaling, 
cardiovascular function and skeletal muscle function. 
Solubility Soluble in water        
Shelf life 
 
Shelf-life of 36 months at 25οC 100 Shelf-life was measured 
under accelerated conditions at 40οC and no loss was observed 
for six months  parts of 95% alcohol dissolves 0.004 parts at 
17οC; insoluble in absolute alcohol 
Mechanism Reduces oxidative stress on cardiac and muscle tissue in the 
presence oxidative stress can protect against damage from 
ischemia-reperfusion injury in cardiac tissue. 
 
  
 
 
 
 
 
 
 
MATERIAL AND METHODS 
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REQUIRED INSTRUMENT AND REAGENT 
              The following table lists the instruments that were used in this study. 
S.N
o 
Name of the 
Instrument Ref. Number Make Model 
1. Electronic balance I/RD/OEB/EB/01 
Adventurer 
OHAUS 
AR2140 
2. HPLC I/RD/HPC/03 Shimadzu  LC-2010C HT 
3. HPLC I/RD/HPC/03 Agilent  1260 Series 
Materials  
              The following table lists the materials that were used in this study. 
S.N
o 
Name Grade Supplier Lot No or 
B.No 
Potency 
/ Purity 
Expiry 
1. Potassiumdihydrogen ortho phosphate AR Rankem J037C16 100.0% Feb 20 
2. Phosphoric acid AR Rankem G025J15 88.0% Sep 18 
3. Sodium metabisulphite AR Rankem J042F09 95.0% Jun 18 
4. Sodium acetate anhydrous AR Fisher 22217301-7 98.0% Jan 2018 
5. Sodium acetate anhydrous AR Rankem G517L18 98.0% Oct 2017 
6. Triethylamine AR Rankem R013H14 99.5% Aug 2019 
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7. Tetrahydrofuran HPLC Fisher 4568920815 99.8% Jul 2020 
8. Glacial acetic acid AR Rankem W015E13 99.8% May 2018 
9. Boric acid AR Rankem N009L12 99.5% Jan 2018 
10. O-Phthaldehyde AR SRL 8740689 99.0% May 2021 
11. Sodium hydroxide AR Fisher 2611860815 98.0% Jul 2020 
12. Potassium hydroxide AR Rankem P14C100872 85.0% Feb 2019 
13. Mercapto ethanol AR Loba D257F1253 95.0% Oct 2018 
14. Methanol HPLC Fisher 1572151116 99.9% Oct 2021 
15. Acetonitrile HPLC Finar 21246112482 99.9% Jan 2022 
Working standard           
           The following table lists the standards that were used in this study. 
S.No Name Grade Lot No./B.No Potency/Purity Date of expiry 
1. Acetylcysteine   USP WS023/10 99.67% 14/09/2017 
2. Taurine USP WS075/09 99.80% 14/09/2017 
Column details 
            The following table lists the column that was used in this study. 
Column Ref. Number I.D. Number Make Specification 
1. RD/COL/76 K63402 Nacalai Tesque,Inc. 
Cosmosil,5C18-MS-II 
(250 X 4.6 mm, 5µm) 
    2. RD/COL/58 H15-005968 Phenomenex 
Phenomenex, Hyperclone ODS 
(C18),120A   250 X 4.6mm, 5µm 
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ANALYTICAL METHOD DEVELOPMENT 
Introduction 
           Analytical method development work is carried out to ensure that the API used 
and dosage forms that are developed and manufactured for human consumption are 
meeting the regulated quality norms before starting the analytical reference will be taken 
based on PDP/Pharmacopoeia /tech peak/PMF and tentative specification. 
            For chromatographic method development following points shall be considered  
             a) Literature review 
             b) Chemical structure and nature of component 
             c) Solubility of component 
              d) Any other relevant 
Method development of HPLC  
           The following parameters are usually considered during method development by 
HPLC 
 Selection of mobile phase 
 Selection of stationary phase 
 Selection of pH 
 Selection of other parameters 
Selection of mobile phase 
Mobile phase A  
            Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
1000 mL of water. Add 0.18 mL of triethylamine and adjust the pH to 7.2 using dilute 
acetic acid and then add 3.0 mL of tetrahydrofuran. Mix well, filter and degas. 
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Mobile phase B 
             Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
200mL of water. Adjust the pH to 7.2 using dilute acetic acid and then add 400 mL of 
acetonitrile and 400 mL of methanol.  Mix well, filter and degas. Mobile phase A and 
mobile phase B mix with 50:50 give satisfactory result of taurine. Various mobile phase 
systems containing phosphate buffer and pH was adjusted to 3 with phosphoric acid, 
that it was observed resolution was satisfactory gives satisfactory result and two well 
resolved peaks for acetylcysteine and taurine were recorded.     
Effect of pH 
            It was observed that the retention of the analyte increase with pH and decrease 
with in pH it was also observed that the shape of peak becomes in basic pH from the 
chromatographic conditions, it was that the pH 3 is suitable for acetylcysteine and pH 
7.2 is suitable for taurine. 
Selection of phase    
           On the basis of HPLC mode and number of carbon atom present in molecule 
C18bonded stationary phase was tried. Cosmosil, C18, 250 X 4.6 mm, 5 μm or 
equivalent, Phenomenex, Hyperclone ODS (C18), 120A   250 X 4,6mm, 5µm for this two 
stationary phase was selected as it gives good result in case of system suitability 
parameter i.e. resolution, USP tangent, USP tailing. 
Selection of other parameter 
           Other parameter like mobile phase, flow rate, column, temperature and 
wavelength of detector can be selected on the basis of chemical properties of 
components present in the sample sensitivity and system suitability requirement of the 
analytical method. 
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TRIAL METHODS 
             Initial condition were from taurine in tablet dosage form  
Parameter      Trial method 1        Trial method 2       Trial method 3 
Flow rate  1 mL/ mins 1 mL/ mins 1 mL/ mins 
Mobile 
phase   
Mobile phase A and 
B (40:60) 
Mobile phase A and B 
(30:70) 
Mobile phase A and B 
(50:50) 
Buffer pH 7.2 7.2 7.2 
Diluent Mix equal volume 
of mobile phase A 
and B  
Mix equal volume of 
mobile phase A and B 
Mix equal volume of 
mobile phase A and B 
Column  Cosmosil,C18,250 X 
4.6 mm,5 μm or 
equivalent  
Cosmosil,C18,250 X 
4.6 mm, 5 μm or 
equivalent 
Cosmosil,C18,250×4.6m
m5μm or equivalent 
Preparation of mobile phase  
 Mobile phase A  
          Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
1000 mL of water. Add 0.18 mL of triethylamine and adjust the pH to 7.2 using dilute 
acetic acid and then add 3.0 mL of tetrahydrofuran. Mix well, filter and degas. 
 Mobile phase B 
           Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
200 mL of water. Adjust the pH to 7.2 using dilute acetic acid and then add 400 mL of 
acetonitrile and 400 mL of methanol. Mix well, filter and degas.  
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         Standard solution 
          Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask.  Add 30 mL of diluent and sonicate for 10 minutes. Make up the 
volume to 50 mL with the diluent and mix well. Dilute 5 mL of this solution to 50 mL with 
the diluent. 
Test solution 
                        Weigh and crush 20 tablets to a fine powder. Weigh accurately about 420mg of 
powdered tablet into clean, 50 mL volumetric flask.  Add 30 mL of diluent and sonicate 
for 10 minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 
5 mL of the filtrate to 50 mL with the diluent. 
                         Separately inject 10μL of standard and test solution into the chromatogram and 
measure the response for taurine. 
           Conclusion  
                    Trial method 1:  Peak was not split so the column was not suitable. 
                    Trial method 2:  Peak was not split so the column was not suitable. 
                    Trial method 3: The peak was well separated and this method has satisfactory 
resolution. Therefore this method was suitable for analysis. 
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OPTIMIZED METHOD 
             Initial condition were from taurine in tablet dosage form  
 Preparation of mobile phase 
 Mobile phase A  
          Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
1000 mL of water. Add 0.18 mL of triethylamine and adjust the pH to 7.2 using dilute 
acetic acid and then add 3.0 mL of tetrahydrofuran. Mix well, filter and degas. 
 Mobile phase B 
           Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
200 mL of water. Adjust the pH to 7.2 using dilute acetic acid and then add 400 mL of 
acetonitrile and 400 mL of methanol.  Mix well, filter and degas.  
Chromatographic conditions  
Column   : Cosmosil, C18, 250 X 4.6 mm, 5 μm or equivalent 
Flow rate   : 1.0 mL / min 
Detection wavelength : 338 nm 
Injection volume  : 10 μL (Online derivatisation method) 
      Borate buffer: OPA reagent: Sample / Standard  
                                       In the ratio 5: 3: 3 (Use injector program) 
Oven temperature  : 40°C 
Mobile phase  : Mobile phase A: Mobile phase B (50: 50) 
Diluent   : Mix each 200 mL of mobile phase A and B in a 500 mL  
                   stopper flask. 
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Standard solution 
          Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask.  Add 30 mL of diluent and sonicate for 10 minutes. Make up the 
volume to 50 mL with the diluent and mix well. Dilute 5 mL of this solution to 50 mL with 
the diluent. 
Test solution 
                           Weigh and crush 20 tablets to a fine powder. Weigh accurately about 420mg 
of powdered tablet into clean, 50 mL volumetric flask.  Add 30 mL of diluent and 
sonicate for 10 minutes.  Make up the volume to 50 mL with the diluent, mix well and 
filter. Dilute 5 mL of the filtrate to 50 mL with the diluent. 
                          Separately inject 10μL of standard and test solution into the chromatogram 
and measure the response for taurine. 
           Conclusion  
                    The peak was well separated and this method has satisfactory resolution. 
Therefore this method was suitable for analysis. 
System stability testing 
              It is an integral of many analytical procedures. This based on the concept that 
the equipment electronics analytical operation and samples. 
Specification limit 
              98% to 102% w/w of the label claim.  
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TRIAL METHODS 
           Initial condition were from acetylcysteine in tablet dosage form 
Parameter       Trial method 1        Trial method 2       Trial method 3 
Flow rate  1 mL/ mins 1 mL/ mins 1 mL/ mins 
Mobile 
phase   
100% buffer  100% buffer  100% buffer  
Buffer pH 7.2 4.5 3 
Diluent Sodium 
metabisulfite(6.8g/L) 
Sodium 
metabisulfite(6.8g/L) 
Sodium 
metabisulfite(6.8g/L) 
Column  Cosmosil,C18,250X4.
6 mm, 5μm or 
equivalent  
Cosmosil,C18,250X4.6
mm 5μm or equivalent 
Cosmosil,C18,250X4.6
mm 5μm or equivalent
Buffer preparation 
        Dissolve 6.8g of monobasic potassium phosphate in 1000mL of water, filter and 
degas. Adjust the pH to 4.5 with phosphoric acid. 
Sodium metabisulfite solution 
           Weigh accurately about 500 mg of sodium metabisulfite and dissolve in 1000mL 
of water. 
Standard solution 
           Weigh accurately about 50 mg of acetylcysteine working standard in 100 mL 
volumetric flask, add 50 mL of sodium metabisulfite solution, dissolve and make up the 
volume with sodium metabisulfite solution. 
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Test solution 
             Weigh and powder 20 tablets. Weigh accurately about 275 mg of powdered 
tablets into a clean, 100mL volumetric flask.  Add 50mL of sodium metabisulfite solution 
and sonicate for 60 minutes.  Make up the volume to 100mL with sodium metabisulfite 
solution, mix well and filter. Use the filtrate.  
           Conclusion  
                    Trial method 1: The peak was not split so the column was not suitable. 
        Trial method 2: The peak was not split so the column was not suitable.              
        Trial method 3: The peak was well separated and this method has satisfactory 
resolution. Therefore this method was suitable for analysis. 
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OPTIMIZED METHOD 
            Initial condition were from acetylcysteine in tablet dosage form 
Chromatographic conditions 
Column            : Cosmosil, C18, 250 X 4.6 mm, 5 μm or equivalent 
Flow rate   : 1.0 mL / min 
Detection wavelength  : 214 nm 
Injection volume  : 10 μL  
Oven temperature  : 30°C 
Mobile phase             : 100% Buffer 
Buffer preparation 
        Dissolve 6.8g of monobasic potassium phosphate in 1000mL of water, filter and 
degas. Adjust the pH to 3.0 with phosphoric acid. 
Sodium metabisulfite solution 
       Weigh accurately about 500 mg of sodium metabisulfite and dissolve in 1000mL of 
water. 
Standard solution 
          Weigh accurately about 50 mg of acetylcysteine working standard in 100 mL 
volumetric flask, add 50 mL of sodium metabisulfite solution, dissolve and make up the 
volume with sodium metabisulfite solution. 
Test solution 
             Weigh and powder 20 tablets. Weigh accurately about 275 mg of powdered 
tablets into a clean, 100mL volumetric flask.  Add 50mL of sodium metabisulfite solution 
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and sonicate for 60 minutes.  Make up the volume to 100mL with sodium metabisulfite 
solution, mix well and filter. Use the filtrate.  
            Conclusion  
                        The peak was well separated and these methods have satisfactory resolution. 
Therefore this method was suitable for analysis. 
System stability testing 
              It is an integral of many analytical procedures. This based on the concept that 
the equipment electronics analytical operation and samples. 
Specification limit 
              98% to 102%w/w of the label claim. 
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ACETYLCYSTEINE 
Reference 
            USP and ICH Guidelines 
Chromatographic conditions  
Column   : Cosmosil, C18, 250 X 4.6 mm, 5 μm or equivalent 
Flow rate   : 1.0 mL / min 
Detection wavelength         : 214 nm 
Injection volume            : 10 μL  
Oven temperature            : 30°C 
Mobile phase             : 100% Buffer 
Buffer preparation 
           Dissolve 6.8g of monobasic potassium phosphate in 1000mL of water, filter and 
degas. Adjust the pH to 3.0 with phosphoric acid. 
Sodium metabisulfite solution 
           Weigh accurately about 500 mg of sodium metabisulfite and dissolve in 1000mL 
of water. 
Standard solution 
           Weigh accurately about 50 mg of acetylcysteine working standard in 100 mL 
volumetric flask, add 50 mL of sodium metabisulfite solution, dissolve and make up the 
volume with sodium metabisulfite solution. 
Test solution 
           Weigh and powder 20 tablets. Weigh accurately about 275 mg of powdered 
tablets into a clean, 100mL volumetric flask.  Add 50mL of sodium metabisulfite solution 
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and sonicate for 60 minutes.  Make up the volume to 100mL with sodium metabisulfite 
solution, mix well and filter. Use the filtrate.  
Procedure 
           Separately inject the standard solution (6 injections) and test solution (2 
injections) into the chromatograph and record the major responses. Ensure the 
following system suitability parameter. 
System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
Calculation 
% Assay of acetylcysteine   
                   Area of sample X Standard wt (mg) X 100 X Purity of std. X  
Avg wt. of tablet (mg) X 100 
                     = ---------------------------------------------------------------------------------------------- 
                                          Area of standard X 100 X Sample wt (mg) X 100 X 150 
                     = --------------- % of acetylcysteine 
 Validation program and acceptance criteria 
 Specificity 
           Analyze the placebo (excipients with taurine) and acetylcysteine separately.  
Placebo solution 
           Weigh accurately about 225.0 mg of placebo into a clean, 100 mL volumetric 
flask.  Add 50 mL of sodium metabisulfite solution and sonicate for 60 minutes.  Make 
up the volume to 100 mL with sodium metabisulfite solution, mix well and filter. Use the 
filtrate (concentration: 2.25 mg/mL of placebo). 
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Standard solution 
            Weigh accurately about 50 mg of acetylcysteine  working standard in 100 mL 
volumetric flask, add 50 mL of sodium metabisulfite solution, dissolve and make up the 
volume with sodium metabisulfite solution (concentration: 0.50 mg/mL of 
acetylcysteine). 
Standard + placebo solution 
            Weigh accurately about 225mg of placebo and 50mg of acetylcysteine working 
standard into a clean, 100 mL volumetric flask.  Add 50 mL of sodium metabisulfite 
solution and sonicate for 60 minutes.  Make up the volume to 100 mL with sodium 
metabisulfite solution, mix well and filter. Use the filtrate (concentration: 2.25 mg/mL of 
placebo and 0.50 mg/mL of acetylcysteine). 
Procedure 
           Prepare the above solution and inject each solution as per the test method and 
report the results. 
Acceptance criteria  
            The placebo chromatogram should not show any peak at the retention time of 
acetylcysteine. 
System precision 
Standard solution 
            Prepare the concentration of acetylcysteine 0.50 mg/mL. 
Procedure 
            Inject the standard solution (6 injections). Ensure the following system suitability 
criteria 
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System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
 
Linearity and Range 
Level - I (50%): 
             Prepare the concentration of 0.25mg/mL of acetylcysteine.   
Level - II (80%): 
            Prepare the concentration of 0.40mg/mL of acetylcysteine.   
Level - III (100%): 
            Prepare the concentration of 0.50mg/mL of acetylcysteine.   
Level - IV (120%):               
            Prepare the concentration of 0.60mg/mL of acetylcysteine.    
Level - V (150%):      
            Prepare the concentration of 0.75mg/mL of acetylcysteine.   
Procedure 
           Prepare the above solutions ranging from 50% to 150% and inject each level in 
duplicate. Perform the correlation co-efficient by covering at least five points and report 
the linearity as the range for determining the assay. 
Acceptance criteria  
           The plot of concentration versus peak area should be linear with a correlation 
coefficient not less than 0.995.      
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Accuracy 
Level - I (50%) – 1: 
           Weigh accurately about 225 mg of placebo and 25 mg of acetylcysteine working 
standard into a clean, 100 mL volumetric flask.  Add 50 mL of sodium metabisulfite 
solution and sonicate for 60 minutes.  Make up the volume to 100 mL with sodium 
metabisulfite solution, mix well and filter. Use the filtrate (concentration: 2.25 mg/mL of 
placebo and 0.25 mg/mL of acetylcysteine).  
Level - I (50%) – 2: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.25 mg/mL of 
acetylcysteine.   
Level - I (50%) – 3: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.25 mg/mL of 
acetylcysteine.   
Level - II (100%) – 1: 
            Weigh accurately about 225.0 mg of placebo and 50 mg of acetylcysteine 
working standard into a clean, 100 mL volumetric flask.  Add 50 mL of sodium 
metabisulfite solution and sonicate for 60 minutes. Make up the volume to 100 mL with 
sodium metabisulfite solution, mix well and filter. Use the filtrate (concentration: 2.25 
mg/mL of placebo and 0.50 mg/mL of acetylcysteine). 
Level - II (100%) – 2: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.50 mg/mL of 
acetylcysteine.   
Level - II (100%) – 3: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.50 mg/mL of 
acetylcysteine.   
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Level - III (150%) – 1: 
            Weigh accurately about 225 mg of placebo and 75 mg of acetylcysteine working 
standard into a clean, 100 mL volumetric flask. Add 50 mL of sodium metabisulfite 
solution and sonicate for 60 minutes. Make up the volume to 100 mL with sodium 
metabisulfite solution, mix well and filter. Use the filtrate (concentration: 2.25 mg/mL of 
placebo and 0.75 mg/mL of acetylcysteine). 
Level - III (150%) – 2: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.75 mg/mL of 
acetylcysteine. 
Level - III (150%) – 3: 
            Prepare the concentration 2.25 mg/mL of placebo and 0.75 mg/mL of 
acetylcysteine. 
Procedure  
            Prepare the above solutions in the range of from 50%, 100% and 150% and 
inject. Each solution in duplicate as per the test method. Calculate the recovery in each 
level by calculating the measured concentration against theoretical concentration. 
Acceptance criteria  
            The recovery should be in the range of 98.0-102.0%. 
Method precision 
            The system precision test as per the test methods.  
Test solution  
            Weigh and powder 20 tablets. Weigh accurately about 275mg of powdered 
tablets into a clean, 100 mL volumetric flask.  Add 50 mL of sodium metabisulfite 
solution and sonicate for 60 minutes. Make up the volume to 100 mL with sodium 
metabisulfite solution, mix well and filter. Use the filtrate (concentration: equivalent to 
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0.50 mg/mL of acetylcysteine). Prepare the equivalent concentration of 0.50 mg/mL of 
acetylcysteine test solution in 6 times. 
 Procedure 
            Prepare the test solution of tablet dosage form as per the test method and inject 
each solution. Calculate the precision of the method by calculating % assay of each 
solution against standard solution. Report the % RSD of all individual assay values. 
Acceptance criteria  
            The percentage relative standard deviation for the assay values should be less 
than 2. 
 Ruggedness (Intermediate precision) 
            The ruggedness of the method is to be performing by analyzing the test solution 
of tablet dosage form with the following varying parameters. 
 
Parameter Set I Set II 
Instrument to instrument Instrument - 1 Instrument - 2 
Column to column Column – 1 Column - 2 
Reagent to reagent Reagent – 1 Reagent - 2 
Analyst to analyst Analyst – 1 Analyst - 2 
Day to day Day – 1 Day - 2 
 
Standard solution 
            Proceed the system precision test as per the test methods.  
Test solution - 1  
            Weigh and powder 20 tablets. Weigh accurately about 275 mg of powdered 
tablets into a clean, 100 mL volumetric flask.  Add 50 mL of sodium metabisulfite 
solution and sonicate for 60 minutes. Make up the volume to 100 mL with sodium 
metabisulfite solution, mix well and filter. Use the filtrate (concentration: equivalent to 
Arulmigu Kalasalingam College Of Pharmacy 
 
Department of Pharmaceutical Analysis  Page 36 
 
0.50 mg/mL of acetylcysteine). Prepare the equivalent concentration of 0.50 mg/mL of 
acetylcysteine test solution in 6 times.  
Procedure 
            Prepare the test solution of tablet dosage form by different analyst with different 
reagent on different day as per the test method. Inject each solution with different 
instrument using different column. Calculate the ruggedness of the method by 
calculating % assay of each solution against standard solution. Report the overall % 
RSD of all individual assay values in set-I and set–II. 
Acceptance criteria 
            The overall % RSD should not be more than 2.0%. 
 Robustness 
            The robustness of the method is to be determined by analyzing the standard 
solution six times with varying HPLC conditions as described below: 
 
Parameter / Condition Actual Low High 
Flow rate 1.00 mL/min 0.90 mL/min 1.10 mL/min 
Mobile phase  
100% Buffer 
conc.: 6.8 g / L 
100% Buffer 
conc.: 6.7 g / L 
100% Buffer 
conc.: 6.9 g / L 
Buffer Ph 3.0 2.9 3.1 
Column oven temperature 30°C 28°C 32°C 
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Acceptance criteria 
 
System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
 
Solution stability 
            Measure the stability of the  tablet dosage form test solution against 100% of the 
standard concentration by keeping the solution up to 48 hours at 15°C. Inject the 
sample at different time intervals (e.g. Initial, 6,12,18,24,36 and 48 hours) and calculate 
the percentage relative standard deviation of acetylcysteine in tablet dosage form at 
different interval of time. 
Acceptance criteria  
           The overall % RSD should not be more than 2.0%.  
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TAURINE 
Reference 
              USP and ICH Guidelines 
Chromatographic conditions  
Column   : Cosmosil, C18, 250 X 4.6 mm, 5 μm or equivalent 
Flow rate   : 1.0 mL / min 
Detection wavelength : 338 nm 
Injection volume  : 10 μL (Online derivatisation method) 
      Borate buffer: OPA reagent: Sample / Standard  
                                       In the ratio 5: 3: 3 (Use injector program) 
Oven temperature  : 40°C 
Mobile phase   : Mobile phase A: Mobile phase B (50: 50) 
Diluent    : Mix each 200mL of mobile phase A and B in a 500mL  
                   stopper flask. 
 Preparation of mobile phase 
 Mobile phase A  
           Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
1000mL of water. Add 0.18mL of triethylamine and adjust the pH to 7.2 using dilute 
acetic acid and then add 3mL of tetrahydrofuran. Mix well, filter and degas. 
Mobile phase B 
            Weigh accurately about 2.72 g of anhydrous sodium acetate and dissolve it in 
200mL of water. Adjust the pH to 7.2 using dilute acetic acid and then add 400mL of 
acetonitrile and 400mL of methanol.  Mix well, filter and degas.   
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Preparation of derivatisation reagents 
45% solution of potassium hydroxide  
           Weigh accurately 4.5 g of potassium hydroxide pellets and dissolve in 10mL of 
water. 
40% solution of sodium hydroxide  
          Weigh accurately 4 g of sodium hydroxide pellets and dissolve in 10mL of water. 
O-phthalaldehyde (OPA) reagent 
          Weigh accurately about 2.47 g of boric acid into 100mL volumetric flask and add 
75mL of water. Shake well to dissolve and adjust the pH of this solution to 10.4 ± 0.1 
with a 45% solution of potassium hydroxide. Make up the volume to 100mL with water.  
           Weigh accurately about 1.0 g of O- phthalaldehyde in a clean 250 mL beaker 
and add 5mL of methanol. Sonicate to dissolve and add 95 mL of borate buffer and 2 
mL of mercapto ethanol and adjust the pH of this solution to 10.4 ± 0.1 with a 40% 
solution of sodium hydroxide.   
Borate buffer pH 10.4 
         Weigh accurately about 2.47 g of boric acid into 100 mL volumetric flask and add 
75mL of water. Shake well to dissolve and adjust the pH of this solution to10.4 ± 0.1 
with a 40 % solution of sodium hydroxide. Make up the volume to 100 mL with water. 
Standard solution 
          Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask.  Add 30 mL of diluent and sonicate for 10 minutes. Make up the 
volume to 50 mL with the diluent and mix well. Dilute 5 mL of this solution to 50 mL with 
the diluent. 
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Test solution 
            Weigh and crush 20 tablets to a fine powder. Weigh accurately about 420mg of 
powdered tablet into clean, 50 mL volumetric flask. Add 30 mL of diluent and sonicate 
for 10 minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 
5 mL of the filtrate to 50 mL with the diluent. 
Procedure 
            Separately inject the standard solution (6 injections) and test solution (2 
injections) into the chromatograph and record the major responses. Ensure the 
following system suitability parameter. 
System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
Calculate the % assay of the taurine using the following expression. 
% Assay of taurine 
Area of sample X Standard wt (mg) X 5 X 50 X 50 X Purity of std. X 
Avg wt. of tablet (mg) X 100 
             = ------------------------------------------------------------------------------------------------- 
Area of standard X 50 X 50 X Sample wt (mg) X 5 X 100 X 500 
                 = --------------- % of taurine 
 Validation program and acceptance criteria 
 Specificity 
        Analyze the placebo (excipients with acetylcysteine) and taurine separately.  
Placebo solution  
        Weigh accurately about 167 mg of placebo into clean, 50 mL volumetric flask. Add 
30 mL of diluent and sonicate for 10 minutes. Make up the volume to 50 mL with the 
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diluent, mix well and filter. Dilute 5 mL of the filtrate to 50 mL with the diluents 
(concentration 0.33 mg/mL of placebo). 
Standard solution (taurine) 
        Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask.  Add 30 mL of diluent and sonicate for 10 minutes. Make up the 
volume to 50 mL with the diluent and mix well. Dilute 5 mL of this solution to 50 mL with 
the diluents (concentration 0.50 mg/mL of taurine). 
Standard + placebo solution 
          Weigh accurately about 167 mg of placebo and 250 mg of taurine working 
standard into clean, 50 mL volumetric flask.  Add 30 mL of diluent and sonicate for 10 
minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 5 mL 
of the filtrate to 50 mL with the diluents (concentration 0.33 mg/mL of placebo and 0.50 
mg/mL of taurine). 
Procedure 
          Prepare the above solution and inject each solution as per the test method and 
report the results. 
Acceptance criteria  
           The placebo chromatogram should not show any peak at the retention time of 
taurine. 
System precision 
Standard solution 
           Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask. Add 30 mL of diluent and sonicate for 10 minutes. Make up the volume 
to 50 mL with the diluent and mix well. Dilute 5 mL of this solution to 50 mL with the 
diluent (concentration: 0.50 mg/mL of taurine). 
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Procedure 
             Inject the standard solution (6 injections). Ensure the following system suitability 
criteria. 
System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
 
Linearity and range 
Standard stock solution 
            Weigh accurately about 250 mg of taurine working standard into clean, 50 mL 
volumetric flask.  Add 30 mL of diluent and sonicate for 10 minutes. Make up the 
volume to 50 mL with the diluent and mix well. 
Level - I (50%): 
           Dilute 2.5 mL of standard stock solution to 50 mL with the diluents 
(concentration: 0.25 mg/mL of taurine). 
Level - II (80%): 
            Dilute 4.0 mL of standard stock solution to 50 mL with the diluents 
(concentration: 0.40 mg/mL of taurine). 
Level - III (100%): 
            Dilute 5.0 mL of standard stock solution to 50 mL with the diluents 
(concentration: 0.50 mg/mL of taurine). 
Level - IV (120%): 
           Dilute 6.0 mL of standard stock solution to 50 mL with the diluent (concentration: 
0.60 mg/mL of taurine). 
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Level - V (150% 
           Dilute 7.5 mL of standard stock solution to 50 mL with the diluent (concentration: 
0.75 mg/mL of taurine). 
Procedure 
            Prepare the above solutions ranging from 50% to 150% and inject each level in 
duplicate.   Perform the correlation co-efficient by covering at least five points and report 
the linearity as the range for determining the assay. 
Acceptance criteria 
            Linear with a correlation coefficient NLT 0.995.      
Accuracy 
Level - I (50%) – 1: 
           Weigh accurately about 167 mg of placebo and 125 mg of taurine working 
standard into clean, 50 mL volumetric flask. Add 30 mL of diluent and sonicate for 10 
minutes. Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 5 mL 
of the filtrate to 50 mL with the diluents (concentration: 0.33 mg/mL of placebo and 0.25 
mg/mL of taurine). 
Level - I (50%) – 2: 
           Prepare the concentration 0.33 mg/mL of placebo and 0.25 mg/mL of taurine. 
Level - I (50%) – 3: 
           Prepare the concentration 0.33 mg/mL of placebo and 0.25 mg/mL of taurine. 
Level - II (100%) – 1: 
             Weigh accurately about 167 mg of placebo and 250 mg of taurine working 
standard into clean, 50 mL volumetric flask.  Add 30 mL of diluent and sonicate for 10 
minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 5 mL 
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of the filtrate to 50 mL with the diluent (concentration: 0.33 mg/mL of placebo and 0.50 
mg/mL of taurine). 
Level - II (100%) – 2: 
            Prepare the concentration 0.33 mg/mL of placebo and 0.50 mg/mL of taurine. 
Level - II (100%) – 3: 
              Prepare the concentration 0.33 mg/mL of placebo and 0.50 mg/mL of taurine. 
Level - III (150%) – 1: 
                Weigh accurately about 167 mg of placebo and 375 mg of taurine working 
standard into clean, 50 mL volumetric flask.  Add 30 mL of diluent and sonicate for 10 
minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 5 mL 
of the filtrate to 50 mL with the diluents (concentration: 0.33 mg/mL of Placebo and 0.75 
mg/mL of taurine). 
Level - III (150%) – 2: 
            Prepare the concentration of 0.33 mg/mL of placebo and 0.75 mg/mL of taurine. 
Level - III (150%) – 3:  
           Prepare the concentration of 0.33 mg/mL of placebo and 0.75 mg/mL of taurine. 
Procedure 
             Prepare the above solutions in the range of from 50%, 100% and 150% and 
inject each solution in duplicate as per the test method. Calculate the recovery in each 
level by calculating the measured concentration against theoretical concentration. 
Acceptance criteria 
             The recovery should be in the range of 98.0-102.0%.  
 
Arulmigu Kalasalingam College Of Pharmacy 
 
Department of Pharmaceutical Analysis  Page 45 
 
Method precision 
Standard solution 
            Proceed the system precision test as per the test methods. 
Test solution  
            Weigh and crush 20 tablets to a fine powder. Weigh accurately about 420 mg of 
powdered tablet into clean, 50 mL volumetric flask. Add 30 mL of diluent and sonicate 
for 10 minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 
5 mL of the filtrate to 50 mL with the diluent (concentration: equivalent to 0.50 mg/mL of 
taurine). Prepare the equivalent concentration 0.50 mg/mL of taurine test solution in 6 
times.  
Procedure 
            Prepare the test solution of tablet dosage form as per the test method and inject 
each solution. Calculate the precision of the method by calculating % assay of each 
solution against standard solution. Report the % RSD of all individual assay values. 
Acceptance criteria 
             The percentage relative standard deviation for the assay values should be less 
than 2.0. 
Ruggedness (Intermediate precision) 
              The ruggedness of the method is to be performing by analyzing the test 
solution of   tablet dosage form with the following varying parameters. 
 
Parameter Set I Set II 
Instrument to instrument Instrument – 1 Instrument - 2 
Column to column Column – 1 Column - 2 
Reagent to reagent Reagent – 1 Reagent - 2 
Analyst to analyst Analyst – 1 Analyst - 2 
Day to day Day – 1 Day - 2 
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Standard solution 
             Proceed the system precision test as per the test method. 
Test solution  
            Weigh and crush 20 tablets to a fine powder. Weigh accurately about 420 mg of 
powdered tablet into clean, 50 mL volumetric flask.  Add 30 mL of diluent and sonicate 
for 10 minutes.  Make up the volume to 50 mL with the diluent, mix well and filter. Dilute 
5 mL of the filtrate to 50 mL with the diluent (concentration equivalent to 0.50 mg/mL of 
taurine). Prepare the equivalent concentration of 0.50 mg/mL of taurine test solution in 6 
times.  
Procedure 
            Prepare the test solution of tablet dosage form by different analyst with different 
reagent on different day as per the test method. Inject each solution with different 
instrument using different column, different reagent, different analyst and different days. 
Calculate the ruggedness of the method by calculating % assay of each solution against 
standard solution. Report the overall % RSD of all individual assay values in set-I and 
set–II. 
Acceptance criteria  
           The overall % RSD should not be more than 2.0%. 
Robustness 
              The robustness of the method is to be determined by analyzing the standard 
solution six times with varying HPLC conditions as described below. 
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Parameter / Condition Actual Low High 
Flow rate 1.00 mL/min 0.90 mL/min 1.10 mL/min 
Mobile phase  
Mobile phase  A : 
Mobile phase  B 
       50 :  50 
Mobile phase  A : 
Mobile phase  B 
       52 :  48 
Mobile phase  A : 
Mobile phase  B 
       48 :  52 
Buffer pH 7.20 7.10 7.30 
Column oven 
temperature 40°C 38°C 42°C 
             
            Acceptance criteria 
System suitability parameter  Accepted criteria  
Tailing factor (standard solution) NMT 2.0 
Column effiencency (standard solution) NLT 2000 theoretical plate 
Relative standard deviation  NMT 2.0 
 
Solution stability 
             Measure the stability of the tablet dosage form test solution against 100% of the 
standard concentration by keeping the solution up to 48 hours at 15°C. Inject the 
sample at different time intervals (eg: Initial, 6 hours, 12 hours, 18 hours and 24 hours) 
and calculate the percentage relative standard deviation of taurine in tablet dosage form 
at different interval of time. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
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RESULTS AND DISCUSSION 
 Specificity 
             Placebo solution was prepared separately at a concentration of 2.25 mg/mL of 
excipients blend. A solution of placebo was spiked with the acetylcysteine at its working 
concentration. The solution was analyzed as per the RP-HPLC method described. 
Table 1 summarizes the retention time (RT), relative retention time (RRT) values 
obtained for placebo and acetylcysteine. 
Acceptance criteria  
           The placebo chromatogram should not show any peak at the retention time of 
acetylcysteine. 
Table 1: Summary of retention time and relative retention time values for placebo and 
acetylcysteine 
Peak name         Retention time (mins)   Relative retention time 
 Blank peak 2.90 0.22 
Acetylcysteine 13.01 1.00 
No peak was observed at the retention time of acetylcysteine in the chromatogram of 
placebo 
 
 
Arulmigu Kalasalingam College Of Pharmacy 
 
Department of Pharmaceutical Analysis  Page 49 
 
 
 
Arulmigu Kalasalingam College Of Pharmacy 
 
Department of Pharmaceutical Analysis  Page 50 
 
 
System precision 
            A standard solution of 0.50 mg/mL of acetylcysteine was prepared and analyzed 
as per the method. Table 2: summarizes system suitability results. 
Acceptance criteria  
(i) The tailing factor for the acetylcysteine peak should not more than 2.0 in standard 
solution.                                                                                                                                                    
(ii) The number of theoretical plates for the acetylcysteine peak should not less than 
2000 in standard solution.                                                                                                                        
Table 2: summary of retention time, % RSD of peak area, tailing factor and 
theoretical plates of the acetylcysteine peak 
S.No 
Retention 
time 
(Minutes) 
Area 
Tailing 
factor 
Theoretica
l plates Average 
% 
RSD 
1 13.18 1900436  
 
 
      1.29 
 
 
 
10788 
  
2 13.18 1890556   
3 13.19 1884890   
4 13.18 1892288 1891268 0.27 
5 13.23 1891080   
6 13.24 1888358   
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                     The percentage relative standard deviation of peak area of acetylcysteine 
was 0.27 with the tailing factor and theoretical plates of 1.29 and 10788 respectively. 
 
Linearity and range     
           The linearity of the HPLC method was demonstrated for acetylcysteine ranging 
from 0.2500 mg/mL to 0.7500 mg/mL, which is equivalent to 50% to 150% of the 
acetylcysteine   working strength. Five standard solutions at the concentrations within 
the mentioned range were prepared and analyzed as per the method. The linearity 
results obtained are shown in Table 3. Figure 1 shows the line of best fit for 
concentration versus peak area of acetylcysteine. 
Acceptance criteria 
         The plot of concentration versus peak area should be linear with a correlation 
coefficient (R2) not less than 0.995. 
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Table 3: Linearity of acetylcysteine 
Level % of acetylcysteine Concentration(mg/mL) Peak area 
50% 0.251 50.2 993424 
80% 0.403 80.6 1583987 
100% 0.508 101.6 1996797 
120% 0.608 121.6 2436183 
150% 0.754 150.8 2980211 
                                                              Correlation coefficient              0.9995 
                                  
 
                         Figure 1: Linearity graph for acetylcysteine   
 Thus, the HPLC method for the estimation of acetylcysteine in tablet dosage form was 
shown to be linear in the range of 50% to 150% of the working concentration with a 
correlation coefficient of 0.9995. The range of the HPLC method for determining the 
assay of acetylcysteine   in tablet dosage form is 50% to 150% of the working strength. 
 
Linearity of Acetylcysteine
y = 4E+06x - 10598
R2 = 0.9995
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Accuracy 
           The accuracy of the method was determined by using three solutions containing 
placebo spiked with acetylcysteine at approximately 50%, 100% and 150% of its 
working strength. Each level was analyzed. The percentage recovery results obtained 
are listed in Table 4.  
Acceptance criteria 
           The recovery should be in the range of 98.0% – 102.0%. 
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                                       Table 4: Accuracy of acetylcysteine 
Level 
%acetylcysteine 
working 
strength 
Theoretical 
conc.(mg/mL) 
Measured 
conc.(mg/mL) 
% 
recovery 
 
50% 
51.0 0.25500 0.25822 101.26 
51.4 0.25700 0.25852 100.59 
50.8 0.25400 0.25772 101.46 
 
100% 
99.8 0.49900 0.50264 100.73 
100.2 0.50100 0.50134 100.07 
100.4 0.50200 0.49767 99.14 
 
150% 
149.4 0.74700 0.74422 99.63 
149.0 0.74500 0.73956 99.27 
150.2 0.75100 0.74264 98.89 
            The percentage recovery values were in the range of 98.89%- 101.46% which is 
within the acceptance criteria. 
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 Method precision 
        The method precision was performed by analyzing a sample solution of tablet 
dosage form                  (six replicate sample preparation). Table 5 summarizes the 
results of precision for the method. 
Acceptance criteria 
            The percentage relative standard deviation for the assay values should be less 
than 2.0. 
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                               Table 5: Summary of results for precision of the method 
Sample Level % Assay 
1 100% 99.92 
2 100% 100.03 
3 100% 99.01 
4 100% 99.58 
5 100% 101.03 
6 100% 100.15 
Average 99.95 
% RSD 0.67 
                  The %RSD for the assay values of acetylcysteine in tablet dosage form was 
0.67 %  
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 Ruggedness (Intermediate precision) 
            The ruggedness of the method was performed by analyzing a sample solution of 
tablet dosage form as per the test method (six replicate samples preparation) and 
injected each solution in duplicate using different instrument, column, reagent, and 
analyst on different days. The results of set I were compared with the results of set II. 
Table 6 shows the ruggedness of the method. 
Acceptance criteria   
            The overall % RSD should not be more than 2.0%  
Table 6: summary of results for ruggedness 
Sample 
% Assay (acetylcysteine) 
Set - I  Set - II  
1 99.92 100.85 
2 100.03 99.23 
3 99.01 99.95 
4 99.58 99.71 
5 101.03 101.19 
6 100.15 99.73 
Average 99.95 100.11 
% RSD 0.67 0.75 
Overall average 100.03 
Overall % RSD 0.68 
Set Set I Set II 
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Instrument I/RD/HPC/04 I/RD/HPC/03 
Column 
        Cosmosil, 5C18-MS-II  
(250 X 4.6 mm, 5µm),         
RD/COL/77 
          Cosmosil, 5C18-MS-II  
(250 X 4.6 mm, 5µm),             
RD/COL/76 
Reagent Potassium dihydrogen        orthophosphate  (Rankem) 
Potassium dihydrogen           
orthophosphate  (Finar) 
Analyst A.Baskar Palraj S.Vijay 
Day 28/02/2017 03/03/2017 
           The above result indicates that the test method is rugged for instrument to 
instrument, column to column, reagent to reagent, analyst to analyst and day to day 
variation. The overall % RSD for the assay value of acetylcysteine in tablet dosage form 
was 0.68.  
 
Robustness  
            The following table (Table 7) shows the parameters of the method that were 
altered to test the robustness of the method. System suitability test was carried out to 
asses if these changes had a significant effect on the chromatography.  
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Table 7:   Parameters altered for robustness test 
Parameter / Condition Actual Low High 
Flow rate 1.00 mL/min 0.90 mL/min 1.10 mL/min 
Mobile phase  
100% Buffer 
Conc.: 6.8 g / L 
100% Buffer 
Conc.: 6.7 g / L 
100% Buffer 
Conc.: 6.9 g / L 
Buffer pH 3.0 2.9 3.1 
Column oven temperature 30°C 28°C 32°C 
            The acetylcysteine results obtained for robustness tests are summarized in 
Table 8. 
Acceptance criteria 
(i) The tailing factor for the acetylcysteine peaks should not more than 2.0 in standard 
solution.                                                                                                                                                     
(ii) The number of theoretical plates for the acetylcysteine peaks should not less than 
2000 in standard solution.                                                                                                                        
(iii) The relative standard deviation for the peak area of acetylcysteine should not be 
more than 2.0% in standard solution. 
          Table 8: Summary of robustness results of acetylcysteine (Flow) 
Flow  Actual  Low  High  
Retention time 
(min) 
13. 18-13.24 14.14-14.18 11.55-11.65 
 Area 1888358-1900436 2145603-2153669 1733324-1754218 
Tailing factor 1.29 1.21 1.20 
Theoretical plates 10788 16721 15359 
Average (Area) 1891268  2152542 1740558 
%RSD (Area) 0.27 0.24 0.41 
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Table 9: Summary of robustness results of acetylcysteine (Mobile phase) 
Mobile phase   Actual  Low  High  
Retention time 
(min) 
13.18_13.24 11.99-12.05 13.25-13.30 
 Area 1888358-
1900436 
1948798-1975414 1852245-1863360 
Tailing factor 1.29  1.131 1.20 
Theoretical plates 10788 15064 15359 
Average (Area) 1891268  1962783 1858564 
%RSD (Area) 0.27 0.57 0.24 
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Table10: Summary of robustness results of acetylcysteine (Buffer pH) 
Buffer pH  Actual Low High 
Retention time (min) 13.18-13.24 12.97-13.05 11.66-11.75 
 Area 1892288-1900436 1879427-1885303 2018685-2034826 
Tailing factor 1.29 1.06 1.09 
Theoretical plates 10788 11501 13554 
Average (Area) 1891268 1890268 2024317 
%RSD (Area) 0.27 0.41 0.30 
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Table 11: Summary of robustness results of acetylcysteine (Column temperature) 
Column 
temperature 
Actual Low High 
Retention time (min) 13.18-13.24 13.20-13.22       12.48-12.49 
 Area 1888358-1900436 1893207-1900998    1896528-1900962 
Tailing factor 1.29 1.16             1.12 
Theoretical plates 10788 15532            1 4663 
Average (Area) 1891268 1895568            1899345 
%RSD (Area) 0.27 0.18             0.09 
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Solution stability 
            A solution of tablet dosage form at 100% of working concentration was kept at 
15°C. The solution stability was monitored at different time interval (Initial, 6 hours, 12 
hours, 24 hours, 36 hours and 48 hours). The results are summarized in Table 12.   
Acceptance criteria 
          Record the results and assign the stability of solutions based on the experimental 
data. The relative standard deviation of assay results should not vary by more than 
2.0% for a stable solution.                       
                           Table 12:   summary of solution stability results 
Time Intervals 
( hours) Initial 6 12 18 24 36 48 
% 
RSD 
         % 
acetylcysteine  
100.43 100.07 101.15 100.63 100.55 100.95 100.7 0.35 
 
              The assay values of acetylcysteine in tablet dosage form was in the range of 
100.07% to 101.15%.The %RSD between the assay results from the initial to 48hours 
was 0.35, which is within the acceptance limit of 2.0%. Therefore, the tablet dosage 
form sample solutions are stable up to 48 hours and 15οC. 
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SUMMARY REPORT OF ACETYLCYSTEINE 
S.No Parameters Observation Acceptance criteria 
1 Specificity 
Placebo 
Interference 
No peak was observed at the 
retention time of acetylcysteine 
in the chromatogram of 
placebo 
The placebo 
chromatogram should not 
show any peak at the 
retention time of 
acetylcysteine. 
2 System precision 
 
1.29 Tailing factor: NMT 2.0 
   10788 Theoretical plates :NLT 
2000 
0.27 % RSD: NMT 2.0 
3 Linearity & range     0.9998 Correlation coefficient: NLT 0.995 
4 Accuracy                       98.89 – 101.46 
% 98.0 – 102.0% 
5 Method precision   0.67 % RSD : NMT 2.0 
(Assay) 
6 Ruggedness           0.68 Overall % RSD NMT 2.0 
(Assay) 
7 Robustness            
  
          1.06 – 1.29 Tailing factor: NMT 2.0 
                 10788 – 16721 Theoretical plates: NLT 2000 
           0.09 – 0.57 % RSD: NMT 2.0 
8 Solution stability    0.35  %RSD NMT : 2.0  
(Assay) 
             
 The results obtained in this study demonstrate that the estimation of 
acetylcysteine in   tablet dosage form by HPLC method described is specific, linear, 
accurate, precise, ruggedness and robust. Therefore, the method is suitable for its 
intended use. 
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Specificity of taurine 
            Placebo solution was prepared separately at a concentration of 0.33 mg/mL of 
excipients blend. A solution of placebo was spiked with the taurine at its working 
concentration. The solution was analyzed as per the RP-HPLC method described. 
Table 1 summarizes the retention time (RT), relative retention time (RRT) values 
obtained for placebo and taurine. 
Acceptance criteria 
           The placebo chromatogram should not show any peak at the retention time of 
taurine. 
                 Table 1: Summary of retention time and relative retention time values for  
                                                  placebo peak of taurine 
Peak name Retention time (minutes) Relative retention time 
Blank peak-1 2.85                        0.50 
Blank peak-2 15.41                       2.70 
Taurine 5.70 1.00 
No peak was observed at the retention time of taurine in the chromatogram of placebo. 
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System precision 
          A standard solution of 0.50 mg/mL of taurine was prepared and analyzed as per 
the method. Table 2 summarizes system suitability results. 
Acceptance criteria  
(i) The tailing factor for the taurine peak should not more than 2.0 in standard solution.                          
(ii) The number of theoretical plates for the taurine peak should not less than 2000 in 
standard solution.                                                                                                                                     
(ii) The relative standard deviation for the peak area of taurine should not be more than 
2.0% in standard solution. 
                Table 2: Summary of retention time, % RSD of peak area, tailing factor 
and  
theoretical plates of the taurine peak 
S.No Retention time (Minutes) Area 
Tailing factor Theoretical plates 
1 5.43 122758536  
 
 
1.56 
 
 
 
10120 
2 5.44 124554851 
3 5.42 123150389 
4 5.41 123847876 
5 5.40 123295736 
6 5.42 123710604 
Average 123552999 
% RSD 0.51 
          The percentage relative standard deviation of peak area of taurine was 0.51 with 
the tailing factor and theoretical plates of 1.56 and 10120 respectively.  
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Linearity and range  
           The linearity of the HPLC method was demonstrated for taurine ranging from 
0.2500 mg/mL to 0.7500 mg/mL, which is equivalent to 50% to 150% of the taurine 
working strength. Five standard solutions at the concentrations within the mentioned 
range were prepared and analyzed as per the method. The linearity results obtained are 
shown in Table 3. Figure 1 shows the line of best fit for concentration versus peak area 
of taurine. 
Acceptance criteria 
             The plot of concentration versus peak area should be linear with a correlation 
coefficient  (R2) not less than 0.995. 
Table 3: Linearity of taurine 
Level % of taurine  Concentration (mg/mL) Peak area 
50% 50.12 0.25060 65341127 
80% 80.19 0.40096 10372708
100% 100.24 0.50120 12412401
120% 120.29 0.60144 15106250
150% 150.36 0.75180 19086289
correlation coefficient 0.9982 
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Figure 2: Linearity graph for taurine 
              Thus, the HPLC method for the estimation of taurine in tablet dosage form was 
shown to be linear in the range of 50% to 150% of the working concentration with a 
correlation coefficient of 0.9982. The range of the HPLC method for determining the 
assay of taurine in tablet dosage form is 50% to 150% of the working strength. 
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Accuracy 
            The accuracy of the method was determined by using three solutions containing 
placebo spiked with taurine at approximately 50%, 100% and 150% of its working 
strength. Each level was analyzed. The percentage recovery results obtained are listed 
in Table 4.  
Acceptance criteria 
           The recovery should be in the range of 98.0% – 102.0%. 
Table 4: Accuracy of taurine 
Level 
% Taurine 
working 
strength 
Theoretical 
conc.(mg/mL) 
Measured 
conc.(mg/mL) % recovery 
 
50% 
50.04 0.25020 0.25045 100.10 
50.24 0.25120 0.25414 101.17 
50.08 0.25040 0.25204 100.65 
 
100% 
100.04 0.50020 0.50262 100.48 
99.96 0.49980 0.49656 99.35 
100.08 0.50040 0.49598 99.12 
150% 
150.48 0.75240 0.76501 101.68 
150.20 0.75100 0.75375 100.37 
150.08 0.75040 0.75919 101.17 
             The percentage recovery values were in the range of 99.12%- 101.68% which 
is within the acceptance criteria. 
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Method precision 
          The method precision was performed by analyzing a sample solution of tablet 
dosage form (B.No: D0349) as per the test method (six replicate sample preparation). 
Table 5 summarizes the results of precision for the method. 
Acceptance criteria 
            The percentage relative standard deviation for the assay values should be less 
than 2.0.  
                     Table 5: Summary of results for precision of the method 
Sample Level % Assay (taurine) 
1 100% 100.48 
2 100% 101.63 
3 100% 101.42 
4 100% 101.09 
5 100% 101.52 
6 100% 101.75 
Average 101.32 
% RSD 0.46 
           The %RSD for the assay values of taurine in tablet dosage form was 0.46. 
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 Ruggedness (Intermediate precision) 
             The ruggedness of the method was performed by analyzing a sample solution 
of tablet dosage form as per the test method (six replicate sample preparation) and 
injected each solution in duplicate using different instrument, column, reagent, and 
analyst on different days. The results of set I were compared with the results of set II. 
Table 6 shows the ruggedness of the method. 
Acceptance criteria 
             The overall % RSD should not be more than 2.0%.  
Table 6: Summary of results for ruggedness 
Sample 
     % Assay (taurine) 
Set - I Set - II 
1 100.48 100.33 
2 101.63 101.40 
3 101.42 99.31 
4 101.09 99.18 
5 101.52 100.28 
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6 101.75 99.77 
Average 101.32 100.05 
% RSD 0.46 0.82 
Overall 
average 100.68 
Overall % RSD 0.91 
Set Set I Set II 
Instrument I/RD/HPC/01 I/RD/HPC/02 
Column 
Cosmosil,5C18-MS-II  
(250 X 4.6 mm, 5µm),              
RD/COL/79 
Phenomenex, Hyperclone-ODS  
250 X 4.6mm, 5µm 
Column ID : RD/COL/58 
Reagent 
Sodium acetate anhydrous 
(Fisher) Methanol (Fisher)             
Acetonitrile (Finar) 
Sodium acetate anhydrous 
(Rankem) Methanol (Finar)            
Acetonitrile (Advent) 
Analyst A.Baskar Palraj R.Chitra 
Day 01/03/2017 07/03/2017 
           The above result indicates that the test method is rugged for instrument to 
instrument, column to column, reagent to reagent, analyst to analyst and day to day 
variation. The overall % RSD for the assay value of taurine in tablet dosage form was 
0.91. 
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 Robustness  
           The following table (Table 7) shows the parameters of the method that were 
altered to test the robustness of the method. System suitability test was carried out to 
asses if these changes had a significant effect on the chromatography.  
                            Table 7:   Parameters altered for robustness test 
Parameter / Condition Actual Low High 
Flow rate 1.00 mL/min 0.90 mL/min 1.10 mL/min 
Mobile phase  
Mobile phase  A 
: Mobile phase  
B 
       50 :  50 
Mobile phase  A 
: Mobile phase  
B 
       52 :  48 
Mobile phase  A : 
Mobile phase  B 
       48 :  52 
Buffer pH 7.20 7.10 7.30 
Column oven 
temperature 40°C 38°C 42°C 
 
Acceptance criteria 
(i) The tailing factor for the taurine peaks should not more than 2.0 in standard solution.                        
(ii) The number of theoretical plates for the taurine peaks should not less than 2000 in 
standard solution.                                                                                                                                     
(iii) The relative standard deviation for the peak area of taurine should not be more than 
2.0% in standard solution. 
The taurine results obtained for robustness tests are summarized in table 8 
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Table 8: Summary of robustness results of taurine (Flow) 
Flow Actual Low High 
Retention time 
(min) 
13.18-13.24 14.14-14.18 11.55-11.65 
 Area 1888358-
1900436 
2145603-
2153669 
1733324-1754218 
Tailing factor 1.29 1.21 1.20 
Theoretical 
plates 
10788 16721 15359 
Average (Area) 1891268  2152542 1740558 
%RSD (Area) 0.27 0.24 0.41 
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Table 9: Summary of robustness results of taurine (Mobile phase) 
Mobile phase  Actual Low High 
Retention time 
(min) 
13.18-13.24 11.99-12.05 13.25-13.30 
 Area 1888358-
1900436 
1948798-
1975414 
1852245-
1863360 
Tailing factor 1.29  1.131 1.20 
Theoretical plates 10788 15064 15359 
Average (Area) 1891268  1962783 1858564 
%RSD (Area) 0.27 0.57 0.24 
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Table10: Summary of robustness results of taurine (Buffer pH) 
Buffer pH Actual Low High 
Retention time 
(min) 
13.18-13.24 12.97-13.05 11.66-11.75 
 Area 1892288-1900436 1879427-1885303 2018685-2034826 
Tailing factor 1.29 1.06 1.09 
Theoretical plates 10788 11501 13554 
Average (Area) 1891268 1890268 2024317 
%RSD (Area) 0.27 0.41 0.30 
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Table 11: Summary of robustness results of taurine (Column temperature) 
Column 
temperature 
Actual Low High 
Retention time (min) 13.18-13.24 13.20-13.22       12.48-12.49 
 Area 1888358-1900436 1893207-1900998    1896528-1900962 
Tailing factor 1.29 1.16             1.12 
Theoretical plates 10788 15532            1 4663 
Average (Area) 1891268 1895568            1899345 
%RSD (Area) 0.27 0.18             0.09 
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Solution stability 
                   A solution of tablet dosage form at 100% of working concentration was kept 
at 15°C. The solution stability was monitored at different time interval (Initial, 6 hours, 12 
hours, and 24 hours). The results are summarized in Table 12.   
Acceptance criteria 
                  Record the results and assign the stability of solutions based on the 
experimental data. The relative standard deviation of assay results should not more 
than 2.0% for a stable solution. 
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Table 12:   Summary of solution stability results 
Time Intervals 
( hours) Initial 6 12 18 24 
% 
RSD 
% taurine   100.17 100.49 101.18 103.06 102.56 1.25 
 
              The assay value of taurine in tablet dosage form was in the range of 100.17% 
to 103.06%. The % RSD between the assay results from the initial to 24 hours was 
1.25, which is within the acceptance limit of 2.0%. Therefore, the tablet dosage form 
sample solutions are stable up to 24 hours at 15°C.  
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SUMMARY REPORT OF TAURINE 
S.
No Parameters Observation Acceptance criteria 
1 Specificity 
Placebo 
interference 
No peak was observed at the 
retention time of taurine in the 
chromatogram of Placebo 
The placebo 
chromatogram should not 
show any peak at the 
retention time of taurine. 
2 System 
precision 
  
1.56 Tailing factor: NMT 2.0 
  10120 Theoretical plates: NLT 
2000 
0.51 % RSD: NMT 2.0 
3 Linearity & 
range     0.9982 
correlation coefficient: 
NLT 0.995 
4 Accuracy                      99.12 – 101.68 % 98.0 – 102.0% 
5 Method 
precision       
0.46 % RSD : NMT: 2.0 
(Assay) 
6 Ruggednes
s                    
0.91 Overall % RSD NMT 2.0  
7 Robustness   
  
           0.81 – 1.56 Tailing factor: NMT 2.0 
               6914 – 11024 Theoretical plates: NLT 2000 
           0.51 – 1.89 % RSD: NMT 2.0 
8 Solution 
stability         
                          1.25 %RSD NMT : 2.0  (Assay) 
 
            The results obtained in this study demonstrate that the estimation of taurine in 
tablet dosage form by RP-HPLC method described is specific, linear, accurate, precise, 
rugged and robust. Therefore, the method is suitable for its intended use. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arulmigu Kalasalingam College Of Pharmacy 
 
Department of Pharmaceutical Analysis  Page 93 
 
CONCLUSION OF ACETYLCYSTEINE 
 Cosmosil, C18, 250×4.6mm 5μm or equivalent as the stationary phase. Mobile phase 
is sodium metabisulphite solution adjusts the pH 3 using ortho phosphoric acid and 
flow rate 1 mL/ mins.   
 Specificity no peak was observed at the retention time of acetylcysteine in the 
chromatogram of placebo. 
 System precision shows %RSD value obtained was below 1. 
 Retention time of acetylcysteine is 13.01. 
 Correlation of coefficient for acetylcysteine is tailing factor of acetylcysteine is 
0.9998.  
 Quantitative estimation of acetylcysteine gives accuracy lies between which 98.89 – 
101.46%  
 By using to system to system suitability and analyst to analyst variability all the 
parameters met the system suitability. 
 Percentage purity of acetylcysteine is 99.67%. 
CONCLUSION OF TAURINE  
 Cosmosil, C18, 250×4.6mm5μm or equivalent as the stationary phase. Mobile phase 
is equally mix the Mobile phase A and B. pH 7.2 and flow rate 1 mL/ mins.   
 Specificity no peak was observed at the retention time of taurine in the 
chromatogram of placebo. 
 System precision shows %RSD value obtained was below 1. 
 Retention time of taurine is 5.41. 
 Correlation of coefficient for taurine is tailing factor of taurine is 1.56. 
 Quantitative estimation of taurine gives accuracy lies between which 99.12 – 101.68 
% 
 By using to system to system suitability and analyst to analyst variability all the 
parameters met the system suitability. 
 Percentage purity of taurine is 99.80%. 
 The results obtained in this study demonstrate that the estimation of taurine in 
tablet dosage form by RP-HPLC method described is specific, linear, accurate, 
precise, rugged and robust. 
The method is suitable for its intended use. 
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GLOSSARY 
 
                                 USP – United States Pharmacopeia 
                                 NMT – Not More Than 
                                 NLT- Not Less Than 
                                 RRT- Relative Retention Time 
                                 RSD- Relative Standard Deviation 
                                 RT- Retention Time 
                                 HPLC- High Performance Liquid Chromatography 
                                 RP-HPLC- Reverse Phase –High performance  
Liquid Chromatography 
                               %- Percentage 
                                Mg – Millie gram  
                               mL- Mille litter 
                               pH-   Potential hydrogen                          
                               Mins- minutes  
                               (R)2 - correlation coefficient  
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